Menopausal Hormone Therapy in Older Women: Examining the Current Balance of Evidence

Drugs Aging. 2023 Aug;40(8):675-683. doi: 10.1007/s40266-023-01043-3. Epub 2023 Jun 21.

Abstract

Menopause occurs in all women. During the menopause transition, 80% of women experience vasomotor symptoms that can last an average of 7-10 years or longer, sometimes into the seventh and eighth decades of life. Understanding how to manage vasomotor symptoms (VMS) in older menopausal women is important since these symptoms can negatively impact quality of life. This review provides a practical guide on how to approach VMS treatment either with menopausal hormone therapy or non-hormone options. When initiating, as well as continuing hormone therapy, the factors clinicians should consider as they weigh risks and benefits include assessing a woman's risks related to cardiovascular disease, breast cancer, and osteoporosis. Utilizing a shared decision-making approach in regard to menopausal symptom management should aim to support women and help them maintain health and quality of life.

Publication types

  • Review

MeSH terms

  • Aged
  • Estrogen Replacement Therapy* / adverse effects
  • Female
  • Hormone Replacement Therapy
  • Humans
  • Menopause
  • Osteoporosis*
  • Quality of Life